Sirona Biochem (TSXV:SBM) Debt-to-Asset : 3.35 (As of Jan. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sirona Biochem Debt-to-Asset?

Sirona Biochem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.79 Mil. Sirona Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$1.56 Mil. Sirona Biochem's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was C$0.70 Mil. Sirona Biochem's debt to asset for the quarter that ended in Jan. 2024 was 3.35.

Sirona Biochem Debt-to-Asset Historical Data

The historical data trend for Sirona Biochem's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirona Biochem Debt-to-Asset Chart

Sirona Biochem Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Asset

Get a 7-Day Free Trial

0.36

0.58

0.66

0.37

2.12

Sirona Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															0.53	1.13	1.51	2.12	3.35

Competitive Comparison of Sirona Biochem's Debt-to-Asset

For the Biotechnology subindustry, Sirona Biochem's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Debt-to-Asset falls into.

Sirona Biochem Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sirona Biochem's Debt-to-Asset for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.644	+	1.539)	/	1.032
	=	2.12

Sirona Biochem's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.791	+	1.556)	/	0.701
	=	3.35

Sirona Biochem (TSXV:SBM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sirona Biochem Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sirona Biochem's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sirona Biochem (TSXV:SBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirona Biochem Corp (TSXV:SBM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SRBCF:USA ZSB:Germany

Address

C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L3

Website

https://www.sironabiochem.com

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. It has a business presence in Canada and France.

Executives

Howard Jarman Verrico

Director, Senior Officer